These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 13954)

  • 1. Altered hepatic blood flow and drug disposition.
    Nies AS; Shand DG; Wilkinson GR
    Clin Pharmacokinet; 1976; 1(2):135-55. PubMed ID: 13954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Commentary: a physiological approach to hepatic drug clearance.
    Wilkinson GR; Shand DG
    Clin Pharmacol Ther; 1975 Oct; 18(4):377-90. PubMed ID: 1164821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow.
    Branch RA; Shand DG; Wilkinson GR; Nies AS
    J Clin Invest; 1974 Apr; 53(4):1101-7. PubMed ID: 4205524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological determinants of altered pharmacokinetics in the elderly.
    Shand DG
    Gerontology; 1982; 28 Suppl 1():8-17. PubMed ID: 7044905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of route of administration and blood flow on hepatic drug elimination.
    Shand DG; Kornhauser DM; Wilkinson GR
    J Pharmacol Exp Ther; 1975 Dec; 195(3):424-32. PubMed ID: 1195129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new model-independent physiological approach to study hepatic drug clearance and its applications.
    Chiou WL
    Int J Clin Pharmacol Ther Toxicol; 1984 Nov; 22(11):577-90. PubMed ID: 6389376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clearance and biologic half-life as indices of intrinsic hepatic metabolism.
    Perrier D; Gibaldi M
    J Pharmacol Exp Ther; 1974 Oct; 191(1):17-24. PubMed ID: 4423599
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of halothane on drug disposition: contribution of changes in intrinsic drug metabolizing capacity and hepatic blood flow.
    Reilly CS; Wood AJ; Koshakji RP; Wood M
    Anesthesiology; 1985 Jul; 63(1):70-6. PubMed ID: 4014773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dispersion model of hepatic elimination: 2. Steady-state considerations--influence of hepatic blood flow, binding within blood, and hepatocellular enzyme activity.
    Roberts MS; Rowland M
    J Pharmacokinet Biopharm; 1986 Jun; 14(3):261-88. PubMed ID: 3783447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Model independent derivation of general equations for the "first-pass" effect and extra-hepatic drug elimination.
    Vaughan
    Eur J Clin Pharmacol; 1977; 11(1):57-64. PubMed ID: 832659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein binding and drug clearance.
    Rowland M
    Clin Pharmacokinet; 1984 Jan; 9 Suppl 1():10-7. PubMed ID: 6705422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance.
    Pang KS; Rowland M
    J Pharmacokinet Biopharm; 1977 Dec; 5(6):625-53. PubMed ID: 599411
    [No Abstract]   [Full Text] [Related]  

  • 13. Hemodynamic drug interactions.
    Nies AS; Shand DG; Branch RA
    Cardiovasc Clin; 1974; 6(2):43-53. PubMed ID: 4613462
    [No Abstract]   [Full Text] [Related]  

  • 14. Drugs as indicators of hepatic function.
    Branch RA
    Hepatology; 1982; 2(1):97-105. PubMed ID: 7054072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Drug dosing in chronic hepatic disease (author's transl)].
    Gugler R; Eichelbaum M
    Leber Magen Darm; 1981 Apr; 11(2):81-7. PubMed ID: 7015045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Models of hepatic drug clearance: discrimination between the 'well stirred' and 'parallel-tube' models.
    Ahmad AB; Bennett PN; Rowland M
    J Pharm Pharmacol; 1983 Apr; 35(4):219-24. PubMed ID: 6133930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose adjustment in patients with liver disease.
    Delcò F; Tchambaz L; Schlienger R; Drewe J; Krähenbühl S
    Drug Saf; 2005; 28(6):529-45. PubMed ID: 15924505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic disease and drug pharmacokinetics.
    Williams RL; Mamelok RD
    Clin Pharmacokinet; 1980; 5(6):528-47. PubMed ID: 7002418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Criticism of pharmacokinetic clearance concepts.
    Keller F; Schoole J
    Int J Clin Pharmacol Ther Toxicol; 1983 Nov; 21(11):563-8. PubMed ID: 6654532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance.
    Rane A; Wilkinson GR; Shand DG
    J Pharmacol Exp Ther; 1977 Feb; 200(2):420-4. PubMed ID: 839445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.